[{"address1": "The Goldyne Savad Institute of Gene Therapy", "address2": "Hadassah Hebrew University Medical Center", "city": "Jerusalem", "zip": "9112001", "country": "Israel", "phone": "972 2 674 3430", "fax": "972 2 643 0982", "website": "https://silexion.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Ilan  Hadar M.B.A.", "age": 54, "title": "Chairman & CEO", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 253614, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mirit Horenshtein Hadar", "age": 39, "title": "EVP of Finance Affairs, CFO & Secretary", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 69977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mitchell  Shirvan M.B.A., Ph.D.", "age": 69, "title": "Chief Scientific & Development Officer", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 206800, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.3359, "open": 0.3424, "dayLow": 0.3326, "dayHigh": 0.46, "regularMarketPreviousClose": 0.3359, "regularMarketOpen": 0.3424, "regularMarketDayLow": 0.3326, "regularMarketDayHigh": 0.46, "beta": -0.192, "volume": 14242520, "regularMarketVolume": 14242520, "averageVolume": 2454065, "averageVolume10days": 683390, "averageDailyVolume10Day": 683390, "bid": 0.3003, "ask": 0.3049, "bidSize": 100, "askSize": 100, "marketCap": 6221127, "fiftyTwoWeekLow": 0.272, "fiftyTwoWeekHigh": 13.558, "fiftyDayAverage": 1.68632, "twoHundredDayAverage": 8.926205, "currency": "USD", "enterpriseValue": 15902696, "sharesOutstanding": 13827800, "sharesShort": 206509, "sharesShortPriorMonth": 226508, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0168, "heldPercentInsiders": 0.33988997, "heldPercentInstitutions": 0.09024999, "shortRatio": 0.05, "impliedSharesOutstanding": 13827800, "bookValue": -67.136, "lastFiscalYearEnd": 1388448000, "nextFiscalYearEnd": 1419984000, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -1355000, "trailingEps": -0.66, "enterpriseToEbitda": -11.736, "52WeekChange": -0.9690892, "SandP52WeekChange": 0.3982091, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SLXN", "underlyingSymbol": "SLXN", "shortName": "Silexion Therapeutics Corp", "longName": "Silexion Therapeutics Corp", "firstTradeDateEpochUtc": 1617802200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "af8f42f8-a6ed-3783-8905-4b79cec71d33", "messageBoardId": "finmb_134350646", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.4499, "recommendationKey": "none", "totalCash": 2781000, "totalCashPerShare": 11.102, "ebitda": -1355000, "totalDebt": 144000, "quickRatio": 3.639, "currentRatio": 3.851, "debtToEquity": 8.944, "returnOnAssets": -0.62134, "returnOnEquity": -1.16659, "freeCashflow": -305625, "operatingCashflow": -794000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-23"}]